339 related articles for article (PubMed ID: 30686077)
1. Complement inhibition as a therapeutic strategy in retinal disorders.
Kassa E; Ciulla TA; Hussain RM; Dugel PU
Expert Opin Biol Ther; 2019 Apr; 19(4):335-342. PubMed ID: 30686077
[TBL] [Abstract][Full Text] [Related]
2. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.
Jaffe GJ; Westby K; Csaky KG; Monés J; Pearlman JA; Patel SS; Joondeph BC; Randolph J; Masonson H; Rezaei KA
Ophthalmology; 2021 Apr; 128(4):576-586. PubMed ID: 32882310
[TBL] [Abstract][Full Text] [Related]
3. Investigational drugs inhibiting complement for the treatment of geographic atrophy.
Ferro Desideri L; Artemiev D; Bernardi E; Paschon K; Zandi S; Zinkernagel M; Anguita R
Expert Opin Investig Drugs; 2023; 32(11):1009-1016. PubMed ID: 37902056
[TBL] [Abstract][Full Text] [Related]
4. Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration.
Yaspan BL; Williams DF; Holz FG; Regillo CD; Li Z; Dressen A; van Lookeren Campagne M; Le KN; Graham RR; Beres T; Bhangale TR; Honigberg LA; Smith A; Henry EC; Ho C; Strauss EC;
Sci Transl Med; 2017 Jun; 9(395):. PubMed ID: 28637922
[TBL] [Abstract][Full Text] [Related]
5. Stargardt macular dystrophy and evolving therapies.
Hussain RM; Ciulla TA; Berrocal AM; Gregori NZ; Flynn HW; Lam BL
Expert Opin Biol Ther; 2018 Oct; 18(10):1049-1059. PubMed ID: 30129371
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials.
Holz FG; Sadda SR; Busbee B; Chew EY; Mitchell P; Tufail A; Brittain C; Ferrara D; Gray S; Honigberg L; Martin J; Tong B; Ehrlich JS; Bressler NM;
JAMA Ophthalmol; 2018 Jun; 136(6):666-677. PubMed ID: 29801123
[TBL] [Abstract][Full Text] [Related]
7. Emixustat and Lampalizumab: Potential Therapeutic Options for Geographic Atrophy.
Jack LS; Sadiq MA; Do DV; Nguyen QD
Dev Ophthalmol; 2016; 55():302-9. PubMed ID: 26501510
[TBL] [Abstract][Full Text] [Related]
8. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study.
Yehoshua Z; de Amorim Garcia Filho CA; Nunes RP; Gregori G; Penha FM; Moshfeghi AA; Zhang K; Sadda S; Feuer W; Rosenfeld PJ
Ophthalmology; 2014 Mar; 121(3):693-701. PubMed ID: 24289920
[TBL] [Abstract][Full Text] [Related]
9. The effect of complement C3 or C5 inhibition on geographic atrophy secondary to age-related macular degeneration: A living systematic review and meta-analysis.
Garg A; Nanji K; Tai F; Phillips M; Zeraatkar D; Garg SJ; Sadda SR; Kaiser PK; Guymer RH; Sivaprasad S; Wykoff CC; Chaudhary V
Surv Ophthalmol; 2024; 69(3):349-361. PubMed ID: 38008405
[TBL] [Abstract][Full Text] [Related]
10. A mechanistic pharmacokinetic/pharmacodynamic model of factor D inhibition in cynomolgus monkeys by lampalizumab for the treatment of geographic atrophy.
Le KN; Gibiansky L; Good J; Davancaze T; van Lookeren Campagne M; Loyet KM; Morimoto A; Jin J; Damico-Beyer LA; Hanley WD
J Pharmacol Exp Ther; 2015 Nov; 355(2):288-96. PubMed ID: 26359312
[TBL] [Abstract][Full Text] [Related]
11. Drug Approval for the Treatment of Geographic Atrophy: How We Got Here and Where We Need to Go.
Csaky KG; Miller JML; Martin DF; Johnson MW
Am J Ophthalmol; 2024 Jul; 263():231-239. PubMed ID: 38387826
[TBL] [Abstract][Full Text] [Related]
12. THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET.
Boyer DS; Schmidt-Erfurth U; van Lookeren Campagne M; Henry EC; Brittain C
Retina; 2017 May; 37(5):819-835. PubMed ID: 27902638
[TBL] [Abstract][Full Text] [Related]
13. The Role of Inflammation in Age-Related Macular Degeneration-Therapeutic Landscapes in Geographic Atrophy.
Borchert GA; Shamsnajafabadi H; Hu ML; De Silva SR; Downes SM; MacLaren RE; Xue K; Cehajic-Kapetanovic J
Cells; 2023 Aug; 12(16):. PubMed ID: 37626902
[TBL] [Abstract][Full Text] [Related]
14. Complement Inhibitors for Advanced Dry Age-Related Macular Degeneration (Geographic Atrophy): Some Light at the End of the Tunnel?
Cruz-Pimentel M; Wu L
J Clin Med; 2023 Aug; 12(15):. PubMed ID: 37568533
[TBL] [Abstract][Full Text] [Related]
15. The complement system: a novel therapeutic target for age-related macular degeneration.
Shughoury A; Sevgi DD; Ciulla TA
Expert Opin Pharmacother; 2023; 24(17):1887-1899. PubMed ID: 37691588
[TBL] [Abstract][Full Text] [Related]
16. Emerging treatments for geographic atrophy in age-related macular degeneration.
Mahmoudzadeh R; Hinkle JW; Hsu J; Garg SJ
Curr Opin Ophthalmol; 2021 May; 32(3):294-300. PubMed ID: 33630787
[TBL] [Abstract][Full Text] [Related]
17. Corticosteroids and Anti-Complement Therapy in Retinal Diseases.
Narayanan R; Kuppermann BD
Handb Exp Pharmacol; 2017; 242():309-320. PubMed ID: 27815789
[TBL] [Abstract][Full Text] [Related]
18. "Izervay (avacincaptad pegol): paving the way for vision preservation in geographic atrophy".
Shakeel L; Khan A; Akilimali A
Ann Med Surg (Lond); 2024 May; 86(5):2413-2416. PubMed ID: 38694318
[TBL] [Abstract][Full Text] [Related]
19. Growth of geographic atrophy on fundus autofluorescence and polymorphisms of CFH, CFB, C3, FHR1-3, and ARMS2 in age-related macular degeneration.
Caire J; Recalde S; Velazquez-Villoria A; Garcia-Garcia L; Reiter N; Anter J; Fernandez-Robredo P; Alfredo García-Layana ;
JAMA Ophthalmol; 2014 May; 132(5):528-34. PubMed ID: 24557084
[TBL] [Abstract][Full Text] [Related]
20. Avacincaptad Pegol: First Approval.
Kang C
Drugs; 2023 Oct; 83(15):1447-1453. PubMed ID: 37814173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
